Replies to post #133088 on Biotech Values

[ariadndndough]

mrk is already calling there's first in class??

.


MK-8931 is a novel, potentially first-in-class, potent ß-site amyloid precursor protein cleaving enzyme (BACE1) inhibitor being investigated for the treatment of Alzheimer's disease. Initiation of a Phase II clinical trial is anticipated in 2012.

[biotech jim]

I thought we had already seen a BACE inhibitor in trials, LLYs Semagacestat and it was not so promising.

LLYs semagacestat is a gamma secretase inhibitor.

First in class generally refers to approved drugs, not to compounds in clinical trials.